Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q15649

UPID:
ZNHI3_HUMAN

ALTERNATIVE NAMES:
HNF-4a coactivator; Thyroid hormone receptor interactor 3; Thyroid receptor-interacting protein 3

ALTERNATIVE UPACC:
Q15649; A8K493; K7EQP1; Q8WVJ3

BACKGROUND:
The protein Zinc finger HIT domain-containing protein 3, with alternative names such as HNF-4a coactivator and Thyroid hormone receptor interactor 3, is integral to various biological functions. Its exact roles and mechanisms in cellular biology are subjects of ongoing research.

THERAPEUTIC SIGNIFICANCE:
Its association with PEHO syndrome, characterized by progressive encephalopathy and severe intellectual disability, underscores the urgent need for targeted therapies. Investigating Zinc finger HIT domain-containing protein 3's function offers a promising pathway to novel treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.